Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Montreal Neurological Institute and Hospital | OTHER |
| McGill University | OTHER |
| Canadian Institutes of Health Research (CIHR) | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Parkinson's disease (PD) affects more than 100,000 Canadians and results in symptoms affecting both motor and cognitive (thinking and memory) functions. Parkinson's disease with Mild Cognitive Impairment (MCI) frequently results in development of dementia for which few treatment options exist. Transcranial Magnetic Stimulation (TMS) is used to alter activity in the outer regions of the brain and has been shown in previous studies to increase cognitive performance in patients with different disorders. This study will investigate the effectiveness of TMS as a clinical treatment for the cognitive deficits associated with Parkinson's disease. 64 male and female participants between the ages of 50 and 90 will attend eight study visits over a period of 63 to 66 days. This study is a double-blind randomized clinical trial meaning the participant will be assigned by chance to either the TMS-treatment group or the Sham-treatment group. Additionally, a combination of memory and thinking tests and Magnetic Resonance Imaging (MRI) will be used to see if there are structural and functional changes within the brain. Genotyping and blood analysis before and after treatment for different biomarkers will also be performed and these data will be compared to the TMS data. Initially, this research will increase knowledge about the effects of TMS on various brain regions. Ultimately, we will be able to determine if TMS can be used as a complementary therapy for PD to improve cognitive performance and to reduce progression into dementia.
Visit 1:
Informed Consent Neuropsychological Battery
Visit 2: (1-2 days later) Blood Draw Neuropsychiatric Assessment Questionnaires Companion Questionnaire to take home UPDRS
Visit 3: (up to a week after visit 2) MRI Scan while performing Executive Task
Visit 4: (1-3 days after visit 3) TMS- or Sham-Treatment (two sessions , 20 min each, 1 hour apart)
Visit 5: (2-3 days after visit 4) Same as Visit 4
Visit 6: (2-3 days after visit 5) Same as Visit 4
Visit 7: (1 day after visit 6) Neuropsychological Battery UPDRS
Visit 8: (1 day after visit 7) MRI Scan while performing Executive Task Blood Draw
Visit 9: (1 month after visit 6) Neuropsychological Battery UPDRS
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PD-MCI, TMS | Active Comparator | The patient is treated with TMS stimulation according to protocol with an active coil. |
|
| PD-MCI, Sham-TMS | Sham Comparator | The patient is treated with Sham-TMS stimulation according to protocol with an inactive coil. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TMS | Device | Real or Sham TMS will be given to the PD-MCI patient |
|
| Measure | Description | Time Frame |
|---|---|---|
| TMS stimulation applied to the left DLPFC has a quantifiable effect on cognition | Changes in one or more of the five assessed brain domains at baseline and one day after stimulation will be measured by comparing the scores for the different neuropsychological tests. The same neuropsychological assessment one month after TMS stimulation will show, if possible changes from one day after are longer lasting and can still be seen. | Neuropsychological Assessments: Baseline, one day after and one month after TMS stimulation |
| Measure | Description | Time Frame |
|---|---|---|
| Change in structural grey and white matter in the brain at baseline compared to after TMS stimulation | MRI analysis will measure any changes in cortical thickness (mm) or other structural changes in the brain after TMS or Sham-TMS stimulation | MRI: Baseline and two days after TMS stimulation |
| Change in executive functioning measured as BOLD fMRI sequence |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Oury Monchi, PhD | University of Calgary | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Calgary, Department of Clinical Neurosciences | Calgary | Alberta | T2N 4N1 | Canada |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33408684 | Derived | Lang S, Gan LS, Yoon EJ, Hanganu A, Kibreab M, Cheetham J, Hammer T, Kathol I, Sarna J, Martino D, Monchi O. Theta-Burst Stimulation for Cognitive Enhancement in Parkinson's Disease With Mild Cognitive Impairment: A Randomized, Double-Blind, Sham-Controlled Trial. Front Neurol. 2020 Dec 21;11:584374. doi: 10.3389/fneur.2020.584374. eCollection 2020. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| D060825 | Cognitive Dysfunction |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
This is a randomized double blind trial.
Not provided
Not provided
The participant and investigator do not know what treatment is applied (TMS stimulation or Sham-TMS stimulation with a different coil).
The outcomes assessor will also be blinded.
| Sham-TMS | Device | Real or Sham TMS will be given to the PD-MCI patient |
|
The executive task, Wisconsin Card Sorting Task, will be performed in the scanner to measure the level of activation in the basal ganglia and the prefrontal cortex via BOLD functional MRI sequence to see changes after TMS stimulation compared to baseline. |
| MRI: Baseline and two days after TMS stimulation |
| Change in levels of biomarkers of interest (alpha-synuclein and BDNF) in serum after TMS stimulation compared to baseline. | Measure the concentration of alpha-synuclein and BDNF in serum at baseline and after TMS stimulation with the Meso Scale Discovery method. These assays are highly developed ELISA assays using electrochemiluminescence. | Blood draws: Baseline and two days after TMS stimulation |
| Genotyping | Analyze DNA for following genes: COMT, DAT1, MAPT, ApoE, GBA, CHCRA4, SNCA, BDNF These genes of interest will be correlated to changes in the neuropsychological assessments. | Blood draw for DNA analysis: Baseline |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |